Lördag 21 December | 19:32:48 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-08-22 13:00 Kvartalsrapport 2025-Q2
2025-06-02 N/A Årsstämma
2025-02-21 08:00 Bokslutskommuniké 2024
2024-11-15 - 15-10 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-06-05 - X-dag ordinarie utdelning S2M 0.00 SEK
2024-06-04 - Årsstämma
2024-02-20 - Bokslutskommuniké 2023
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-06-09 - X-dag ordinarie utdelning S2M 0.00 SEK
2023-06-08 - Årsstämma
2023-05-31 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-06-02 - X-dag ordinarie utdelning S2M 0.00 SEK
2022-06-01 - Årsstämma
2022-05-17 - Kvartalsrapport 2022-Q1
2022-04-14 - Extra Bolagsstämma 2022
2022-02-18 - Bokslutskommuniké 2021
2021-12-30 - Extra Bolagsstämma 2021
2021-11-23 - Kvartalsrapport 2021-Q3
2021-08-23 - Kvartalsrapport 2021-Q2
2021-06-02 - X-dag ordinarie utdelning S2M 0.00 SEK
2021-06-01 - Årsstämma
2021-05-20 - Kvartalsrapport 2021-Q1
2021-03-05 - Bokslutskommuniké 2020
2020-11-23 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-06-12 - X-dag ordinarie utdelning S2M 0.00 SEK
2020-06-11 - Årsstämma
2020-05-22 - Kvartalsrapport 2020-Q1
2020-03-06 - Bokslutskommuniké 2019
2019-11-22 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-05-23 - Kvartalsrapport 2019-Q1
2019-05-17 - X-dag ordinarie utdelning S2M 0.00 SEK
2019-05-16 - Årsstämma
2019-03-06 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
S2Medical är verksamt inom medicinteknik. Bolaget är inriktade mot forskning och utveckling av diverse sårläkningsprodukter. Olika produkter som erbjuds inkluderar cellulosabaserat material och förband för läkning av brännskador, samt kroniska sår. Produkterna säljs under olika varumärken, främst på europeisk nivå. S2Medical grundades under 2013 och har sitt huvudkontor i Linköping.
2023-11-06 16:09:54

S2Medical AB (publ) ("S2Medical"), a leading developer of medical devices, is proud to announce that we have entered into an exclusive distribution agreement with Provas Medical Ltd ("Provas Medical") for the sale of products in the Epiprotect series on the Turkish market.

This three-year agreement marks a significant milestone for S2Medical's expansion and presence in the Middle East and will strengthen the company's position as a pioneer in wound healing. The agreement entails commitments from Provas Medical to place orders worth approximately 4.7 million Swedish kronor, provided that S2Medical's products are successfully registered in Turkey.

Provas Medical has a strong presence in Turkey and will play a key role in introducing the Epiprotect series to the Turkish market. S2Medical looks forward to a successful collaboration with Provas Medical and to improving the quality of life for patients through access to top-tier wound healing.

"We are excited about the partnership with Provas Medical and the opportunities it opens up for S2Medical. This agreement is a testament to the global demand for our Epiprotect products and our ability to expand our reach to new and promising markets," says Mårten Skog, COO of S2Medical AB (publ).

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-11-2023 16:09 CET.